Research and Markets (http://www.researchandmarkets.com/research/46d237/indian_pharmaceuti) has announced the addition of the “Indian Pharmaceutical Industry” report to their offering.
The purpose of this study is to describe the specific segment of the pharmaceutical market sector called the Indian pharmaceutical industry. This sector includes all of the generally-accepted pharmaceutical manufacturing activities that are currently used today, including the bulk drug industry, formulations and major therapeutic segments. It examines these clinical supplies as utilized in hospitals, clinics and doctor’s offices.
The principal objectives of this analysis are to:
1) identify viable technology drivers through a comprehensive look at various platform technologies for the Indian pharmaceutical industry;
2) obtain a complete understanding of the Indian pharmaceutical industry practices from its basic principles to its applications;
3) discover feasible market opportunities via an identification of high-growth applications in different areas of the Indian pharmaceutical industry, with a focus on the biggest and expanding markets for the Indian pharmaceutical industry;
4) focus on global industry development through an in-depth analysis of the major world markets for pharmaceutical manufacturing, including forecasts for growth;
5) establish the essentials of the Indian pharmaceutical market including definitions, processes and trends.
Key Topics Covered:
— Overview
— Introduction
— The Indian Market
— Characteristics of the Indian Pharmaceutical Industry
— Key Players in the Indian Pharmaceutical Industry
— Strategic Groups
— Critical Success Factors (CSF) of the Industry
— Policies and Regulations
— Changing Scenario of Product Patent Regime
— Laws Pertaining to Manufacture and Sale of Drugs in India
— Marketing and Distribution in the Pharmaceutical Industry
— The Changing External Environment
— Porters Five Forces Model
— Future Outlook for the Indian Pharmaceutical Industry
— Emerging Trends
— India – The Clinical Trial Destination
— Risks-Weaknesses and Threats-Faced by Indian Industry
— Intellectual Property and Access to Medicines
— Evolving Indian Drug Research and Development
— Case of a Leading Indian Firm-Ranbaxy Laboratories
— Strategic Options for Pharmaceutical Firms
— How to Build Sustainable Competitive Advantage
Appendix
— Requirements and Guidelines for Permission to Import and/or Manufacture of New Drugs for Sale or to Undertake Clinical Trials Clinical Trial
Studies in Special Populations
— Data to be Submitted Along with the Application to Conduct Clinical Trials/Import/Manufacture of New Drugs for Marketing in India
— Data Required to be Submitted by an Applicant for Grant of Permission to Import and/or Manufacture a New Drug Already Approved in India
— Structure, Contents and Format for Clinical Study Reports
— Animal Toxicology (Non-Clinical Toxicity Studies)
— Non-Clinical Toxicity Testing and Safety Evaluation Data of an Ind Needed for the Conduct of Different Phases of Clinical Trials Animal Pharmacology
— Informed Consent
— Fixed Dose Combinations (FDCs)
— Undertaking by the Investigator
— Ethics Committee
— Stability Testing of New Drugs
— Stability Testing of New Drug Substances and Formulations
— Contents of the Proposed Protocol for Conducting Clinical Trials
— Data Elements for Reporting Serious Adverse Events Occurring in a Clinical Trial
For more information visit http://www.researchandmarkets.com/research/46d237/indian_pharmaceuti
Comments